Selected Publications
Lockwood BJ, El-Jawahri A, Walker AR, Ehrman S, Russell D, Kale SS, Gustin J, Bose-Brill S, LeBlanc TW, Luger SM, Lustberg M, Bhatnagar B.: Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy J Adolesc Young Adult Oncol : 2022.
Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies Transplant Cell Ther : 2022.
Ganzel C, Sun Z, Baslan T, Zhang Y, Gönen M, Abdel-Wahab OI, Racevskis J, Garrett-Bakelman F, Lowe SW, Fernandez HF, Ketterling R, Luger SM, Litzow M, Lazarus HM, Rowe JM, Tallman MS, Levine RL, Paietta E.: Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling Leuk Res 123 : 106971,2022.
Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, Wang ES, Shami PJ, Adekola KUA, Luger SM, Baer MR, Rizzieri DA, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Schuler TA, Leisenring WM, Onstad L, Becker PS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey E.: An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients Blood : 2022.
Aldoss I, Yin J, Wall A, Mrózek K, Liedtke M, Claxton D, Foster MC, Appelbaum FR, Erba HP, Litzow MR, Tallman MS, Stone RM, Larson RA, Advani AS, Stock W, Luger SM.: The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study Blood Adv : 2022.
Freyer, C. W., Babushok, D. V., Frey, N. V., Gill, S. I., Loren, A. W., Luger, S. M., Maity, A., Martin, M. E., Plastaras, J. P., Porter, D. L., Hexner, E. O.: Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis Transplant Cell Ther 28 (9): 590-596,2022.
Freyer, C. W., Carulli, A., Gier, S., Ganetsky, A., Timlin, C., Schuster, M., Babushok, D., Frey, N. V., Gill, S. I., Hexner, E. O., Luger, S. M., Mangan, J. K., Martin, M. E., McCurdy, S. R., Perl, A. E., Porter, D. L., Pratz, K., Smith, J., Stadtmauer, E. A., Loren, A. W.: Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide Leuk Lymphoma 63 (8): 1925-1933,2022.
Graveno, M. E., Carulli, A., Freyer, C. W., Mangan, B. L., Nietupski, R., Loren, A. W., Frey, N. V., Porter, D. L., Gill, S. I., Hexner, E. O., Luger, S. M., Martin, M. E., McCurdy, S. R., Perl, A. E., Babushok, D. V., Pratz, K. W.: Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia Leuk Lymphoma 63 (7): 1645-1650,2022.
Matthews, A. H., Perl, A. E., Luger, S. M., Loren, A. W., Gill, S. I., Porter, D. L., Babushok, D. V., Maillard, I. P., Carroll, M. P., Frey, N. V., Hexner, E. O., Martin, M. E., McCurdy, S. R., Stadtmauer, E. A., Paralkar, V. R., Bruno, X. J., Hwang, W. T., Margolis, D., Pratz, K. W.: Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia Blood Adv 6 (13): 3997-4005,2022.
Muffly, L., Yin, J., Jacobson, S., Wall, A., Quiroz, E., Advani, A. S., Luger, S. M., Tallman, M. S., Litzow, M. R., Foster, M. C., Erba, H. P., Appelbaum, F. R., Larson, R. A., Keegan, T. H. M., Stock, W.: Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia Blood Adv 6 (14): 4085-4092,2022.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-157
34th and Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-614-1847
Patient appointments: 800-789-7366